{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:33:14Z","timestamp":1792801994848,"version":"4.5.0"},"reference-count":214,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Crinetics Pharmaceuticals, Inc","id":[{"id":"https:\/\/ror.org\/02ha0t079","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Appropriate diagnosis and treatment of comorbidities is key to managing acromegaly given their adverse clinical impact on quality of life and survival; thus, it is important to increase overall awareness of complications and their individualized management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence<\/jats:title>\n                    <jats:p>This review examines the current literature on pathophysiology, diagnosis, and clinical presentation of acromegaly complications, as well as impact of acromegaly therapy and current goals for treatment outcomes of these morbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We focus on the most relevant acromegaly comorbidities including cardiorespiratory, metabolic, bone, and oncologic complications. Selected complications that may determine pharmacologic choices are also evaluated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag114","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:57:39Z","timestamp":1773838659000},"page":"S51-S63","source":"Crossref","is-referenced-by-count":6,"title":["Acromegaly complications: an update"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-3398","authenticated-orcid":false,"given":"Andrea","family":"Giustina","sequence":"first","affiliation":[{"name":"Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS San Raffaele Hospital , Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[{"name":"Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University , Portland, OR 97239 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"19","key":"2026060416142680500_dgag114-B1","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMra2409076","article-title":"Acromegaly","volume":"393","author":"Giustina","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"2026060416142680500_dgag114-B2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026060416142680500_dgag114-B3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"3","key":"2026060416142680500_dgag114-B4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"issue":"1","key":"2026060416142680500_dgag114-B5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"9","key":"2026060416142680500_dgag114-B6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"2026060416142680500_dgag114-B7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2026060416142680500_dgag114-B8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1210\/endrev\/bnaf020","article-title":"Medical treatment of acromegaly: navigating the present, shaping the future","volume":"46","author":"Gadelha","year":"2025","journal-title":"Endocr Rev"},{"issue":"12","key":"2026060416142680500_dgag114-B9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/BF03349164","article-title":"Diagnosis and treatment of acromegaly complications","volume":"26","author":"Giustina","year":"2003","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2026060416142680500_dgag114-B10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","article-title":"A consensus on the diagnosis and treatment of acromegaly complications","volume":"16","author":"Melmed","year":"2013","journal-title":"Pituitary"},{"issue":"4","key":"2026060416142680500_dgag114-B11","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060416142680500_dgag114-B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-026-01639-z","article-title":"Consensus on acromegaly complications: an update","author":"Giustina","year":"2026","journal-title":"Pituitary"},{"issue":"2","key":"2026060416142680500_dgag114-B13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11102-025-01503-6","article-title":"Long-term clinical outcome of 103 patients with acromegaly after pituitary surgery","volume":"8","author":"Pennlund","year":"2025","journal-title":"Pituitary"},{"issue":"5","key":"2026060416142680500_dgag114-B14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","article-title":"Pilot study to define criteria for pituitary tumors centers of excellence (PTCOE): results of an audit of leading international centers","volume":"26","author":"Giustina","year":"2023","journal-title":"Pituitary"},{"issue":"4","key":"2026060416142680500_dgag114-B15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","article-title":"Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"24","key":"2026060416142680500_dgag114-B16","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"2026060416142680500_dgag114-B17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fendo.2019.00509","article-title":"Insulin resistance in patients with acromegaly","volume":"10","author":"Vila","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026060416142680500_dgag114-B18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11102-024-01464-2","article-title":"Growth hormone and bone: a basic perspective","volume":"27","author":"Bolamperti","year":"2024","journal-title":"Pituitary"},{"issue":"10","key":"2026060416142680500_dgag114-B19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"2026060416142680500_dgag114-B20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1507\/endocrj.EJ25-0047","article-title":"Body mass index and metabolic complications in individuals with treatment-na\u00efve acromegaly","volume":"72","author":"Yamamoto","year":"2025","journal-title":"Endocr J"},{"issue":"6","key":"2026060416142680500_dgag114-B21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cen.15060","article-title":"Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK Acromegaly Register 1970-2016","volume":"100","author":"Orme","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026060416142680500_dgag114-B22","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/jcm14061906","article-title":"Acromegaly and cardiovascular disease: associated cardiovascular risk factors, cardiovascular prognosis, and therapeutic impact","volume":"14","author":"Iglesias","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"2026060416142680500_dgag114-B23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eem.11.82","article-title":"Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment","volume":"7","author":"Dav\u00ec","year":"2012","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"15","key":"2026060416142680500_dgag114-B24","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9149(99)80721-8","article-title":"Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide","volume":"75","author":"Giustina","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026060416142680500_dgag114-B25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fendo.2019.00120","article-title":"Bringing cardiovascular comorbidities in acromegaly to an update. Should we diagnose and manage them?","volume":"10","author":"Ramos-Lev\u00ed","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2026060416142680500_dgag114-B26","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.eprac.2024.09.014","article-title":"Cardiovascular disorders associated with acromegaly: an update","volume":"30","author":"Sherin","year":"2024","journal-title":"Endocr Pract"},{"key":"2026060416142680500_dgag114-B27","doi-asserted-by":"crossref","first-page":"1260842","DOI":"10.3389\/fendo.2023.1260842","article-title":"Use of speckle tracking echocardiography in evaluating cardiac dysfunction in patients with acromegaly: an update","volume":"14","author":"Huang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026060416142680500_dgag114-B28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11102-024-01403-1","article-title":"The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study","volume":"27","author":"De Alcubierre","year":"2024","journal-title":"Pituitary"},{"key":"2026060416142680500_dgag114-B29","doi-asserted-by":"crossref","first-page":"1630037","DOI":"10.3389\/fendo.2025.1630037","article-title":"Cardiac structure and function recovery in acromegaly after treatment: insights from cardiac magnetic resonance imaging","volume":"16","author":"Chen","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026060416142680500_dgag114-B30","first-page":"1551","article-title":"Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416142680500_dgag114-B31","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ejendo\/lvaf009","article-title":"The effect of first intervention on cardiac parameters in patients with acromegaly: a systematic review","volume":"192","author":"Huynh","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026060416142680500_dgag114-B32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1530\/EJE-15-0500","article-title":"Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study","volume":"173","author":"Kuhn","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026060416142680500_dgag114-B33","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2265.2005.02265.x","article-title":"Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study","volume":"62","author":"Bogazzi","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026060416142680500_dgag114-B34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11102-007-0062-6","article-title":"The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly","volume":"11","author":"De Marinis","year":"2008","journal-title":"Pituitary"},{"issue":"5","key":"2026060416142680500_dgag114-B35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s11102-024-01405-z","article-title":"Cardiovascular risk in patients with acromegaly vs. non-functioning pituitary adenoma following pituitary surgery: an active-comparator cohort study","volume":"27","author":"Stocker","year":"2024","journal-title":"Pituitary"},{"issue":"12","key":"2026060416142680500_dgag114-B36","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s40618-021-01579-4","article-title":"Echocardiographic findings in acromegaly: prevalence of concentric left ventricular remodeling in a large single-center cohort","volume":"44","author":"Hinojosa-Amaya","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2026060416142680500_dgag114-B37","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1210\/clinem\/dgaf338","article-title":"Cardiomyopathy in patients with acromegaly - not truly a concern anymore?","volume":"110","author":"Wolf","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416142680500_dgag114-B38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"issue":"15","key":"2026060416142680500_dgag114-B39","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehab822","article-title":"Acromegaly and cardiovascular outcomes: a cohort study","volume":"43","author":"Hong","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"2026060416142680500_dgag114-B40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-012-9828-3","article-title":"QT dispersion in patients with acromegaly","volume":"43","author":"Unubol","year":"2013","journal-title":"Endocrine"},{"issue":"2","key":"2026060416142680500_dgag114-B41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijcard.2004.12.010","article-title":"Late potentials and ventricular arrhythmias in acromegaly","volume":"104","author":"Maffei","year":"2005","journal-title":"Int J Cardiol"},{"issue":"1","key":"2026060416142680500_dgag114-B42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jcph.213","article-title":"Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single-center, phase I, randomized, four-way crossover study","volume":"54","author":"Breitschaft","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2026060416142680500_dgag114-B43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1210\/jc.2003-030849","article-title":"Increased prevalence of regurgitant valvular heart disease in acromegaly","volume":"89","author":"Pereira","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026060416142680500_dgag114-B44","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3390\/biomedicines12071464","article-title":"Three-dimensional speckle-tracking echocardiography-derived tricuspid annular properties in acromegaly-results from the MAGYAR-path study","volume":"12","author":"Nemes","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"2026060416142680500_dgag114-B45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3390\/biomedicines13030605","article-title":"Echocardiographic findings in cardiomyopathy due to acromegaly","volume":"13","author":"Orihuela Rodr\u00edguez","year":"2025","journal-title":"Biomedicines"},{"issue":"6","key":"2026060416142680500_dgag114-B46","first-page":"797","article-title":"Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly","volume":"19","author":"Izgi","year":"2010","journal-title":"J Heart Valve Dis"},{"issue":"6","key":"2026060416142680500_dgag114-B47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11102-025-01586-1","article-title":"Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly","volume":"28","author":"Araujo-Castro","year":"2025","journal-title":"Pituitary"},{"issue":"4","key":"2026060416142680500_dgag114-B48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2265.2005.02370.x","article-title":"Hypertension in acromegaly and in the normal population: prevalence and determinants","volume":"63","author":"Vitale","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026060416142680500_dgag114-B49","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ecl.2019.08.008","article-title":"Hypertension and acromegaly","volume":"48","author":"Puglisi","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2026060416142680500_dgag114-B50","doi-asserted-by":"crossref","first-page":"577173","DOI":"10.3389\/fendo.2020.577173","article-title":"Hypertension in acromegaly in relationship to biochemical control and mortality: global ACROSTUDY outcomes","volume":"11","author":"Vila","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026060416142680500_dgag114-B51","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1210\/jc.2018-00325","article-title":"Persistence of diabetes and hypertension after multimodal treatment of acromegaly","volume":"103","author":"Gonz\u00e1lez","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416142680500_dgag114-B52","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11102-023-01321-8","article-title":"Importance of 24 h ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings","volume":"26","author":"Rocha","year":"2023","journal-title":"Pituitary"},{"issue":"7","key":"2026060416142680500_dgag114-B53","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/HJH.0000000000000962","article-title":"Role of ambulatory blood pressure monitoring in patients with acromegaly","volume":"34","author":"Costenaro","year":"2016","journal-title":"J Hypertens"},{"issue":"11","key":"2026060416142680500_dgag114-B54","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1210\/jc.2014-2259","article-title":"Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk","volume":"99","author":"Reyes-Vidal","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416142680500_dgag114-B55","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis","volume":"92","author":"Maison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416142680500_dgag114-B56","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026060416142680500_dgag114-B57","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1210\/jc.2011-0078","article-title":"Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416142680500_dgag114-B58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","article-title":"Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities","volume":"20","author":"Pivonello","year":"2017","journal-title":"Pituitary"},{"key":"2026060416142680500_dgag114-B59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.sleep.2021.01.033","article-title":"Impact of obstructive sleep apnea on cardiovascular risk in patients with acromegaly","volume":"80","author":"Cao","year":"2021","journal-title":"Sleep Med"},{"issue":"6","key":"2026060416142680500_dgag114-B60","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s11325-023-02838-9","article-title":"Cardiovascular remodeling in active and controlled acromegaly: association with sleep-disordered breathing","volume":"27","author":"Filchenko","year":"2023","journal-title":"Sleep Breath"},{"issue":"3","key":"2026060416142680500_dgag114-B61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s12020-019-02061-1","article-title":"Sleep disorders and cognitive dysfunction in acromegaly","volume":"66","author":"Wennberg","year":"2019","journal-title":"Endocrine"},{"issue":"1","key":"2026060416142680500_dgag114-B62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF03346696","article-title":"Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (comorbidities evaluation and treatment in acromegaly) Italian study group","volume":"34","author":"De Menis","year":"2011","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026060416142680500_dgag114-B63","doi-asserted-by":"crossref","first-page":"e13602","DOI":"10.1111\/jsr.13602","article-title":"The history of sleep research and sleep medicine in Europe","volume":"31","author":"Schulz","year":"2022","journal-title":"J Sleep Res"},{"issue":"3","key":"2026060416142680500_dgag114-B64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cen.14994","article-title":"High prevalence of severe sleep cycle disruption in de novo acromegaly and underdiagnosis by common clinical screening tools: a prospective, observational, cross-sectional study","volume":"100","author":"Powlson","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2026060416142680500_dgag114-B65","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.5664\/jcsm.10532","article-title":"Application of artificial intelligence in the diagnosis of sleep apnea","volume":"19","author":"Bazoukis","year":"2023","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"2026060416142680500_dgag114-B66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11102-025-01534-z","article-title":"Artificial intelligence in acromegaly: why, when and how","volume":"28","author":"Giustina","year":"2025","journal-title":"Pituitary"},{"issue":"6","key":"2026060416142680500_dgag114-B67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EJE-09-0694","article-title":"Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly","volume":"161","author":"Berg","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060416142680500_dgag114-B68","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3803\/EnM.2024.1933","article-title":"Obstructive sleep apnea screening and effects of surgery in acromegaly: a prospective study","volume":"39","author":"Cho","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"2026060416142680500_dgag114-B69","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/clinem\/dgz050","article-title":"The course of obstructive sleep apnea syndrome in patients with acromegaly during treatment","volume":"105","author":"Wolters","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416142680500_dgag114-B70","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-08-0442","article-title":"Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease","volume":"159","author":"Davi\u2019","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060416142680500_dgag114-B71","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"Annamalai","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026060416142680500_dgag114-B72","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1210\/jc.2003-030462","article-title":"Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly","volume":"88","author":"Spinelli","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416142680500_dgag114-B73","first-page":"1518","article-title":"Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416142680500_dgag114-B74","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/er.2003-0009","article-title":"Cardiovascular function in acromegaly","volume":"24","author":"Clayton","year":"2003","journal-title":"Endocr Rev"},{"issue":"1","key":"2026060416142680500_dgag114-B75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/EJE-16-1080","article-title":"Assessment of lung function in a large cohort of patients with acromegaly","volume":"177","author":"St\u00f6rmann","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026060416142680500_dgag114-B76","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11102-025-01585-2","article-title":"Exercise ventilatory inefficiency may be a specific feature of patients with acromegaly","volume":"28","author":"Dorelli","year":"2025","journal-title":"Pituitary"},{"issue":"3","key":"2026060416142680500_dgag114-B77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-025-01539-8","article-title":"Muscle dysfunction is associated with poor quality of life in long-term controlled patients with acromegaly","volume":"28","author":"Martel-Duguech","year":"2025","journal-title":"Pituitary"},{"issue":"9","key":"2026060416142680500_dgag114-B78","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s40618-025-02624-2","article-title":"Sarcopenic obesity and physical function in acromegaly: impact of disease control and evaluation using dual X-ray absorptiometry and multifrequency bioelectrical impedance analysis","volume":"48","author":"Inojosa","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2026060416142680500_dgag114-B79","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1530\/eje.0.1340554","article-title":"Octreotide treatment increases exercise capacity in patients with acromegaly","volume":"134","author":"Padayatty","year":"1996","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060416142680500_dgag114-B80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2265.2003.01689.x","article-title":"Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide","volume":"58","author":"Colao","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026060416142680500_dgag114-B81","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2265.2002.01476.x","article-title":"Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess","volume":"56","author":"Thomas","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026060416142680500_dgag114-B82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/cen.12708","article-title":"Physical and cardiovascular performance in cases with acromegaly after regular short-term exercise","volume":"83","author":"Hatipoglu","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026060416142680500_dgag114-B83","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2026060416142680500_dgag114-B84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11102-023-01322-7","article-title":"Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines","volume":"26","author":"Slagboom","year":"2023","journal-title":"Pituitary"},{"issue":"7","key":"2026060416142680500_dgag114-B85","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","article-title":"Current and emerging aspects of diabetes mellitus in acromegaly","volume":"27","author":"Frara","year":"2016","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"2026060416142680500_dgag114-B86","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41574-024-00993-x","article-title":"Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management","volume":"20","author":"Esposito","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2026060416142680500_dgag114-B87","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1210\/clinem\/dgac400","article-title":"Effect of diabetes on morbidity and mortality in patients with acromegaly","volume":"107","author":"Esposito","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416142680500_dgag114-B88","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000144046","article-title":"Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test","volume":"88","author":"Mazziotti","year":"2008","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2026060416142680500_dgag114-B89","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/EJE-20-0497","article-title":"Metabolic complications in acromegaly after neurosurgery: a meta-analysis","volume":"183","author":"Cozzolino","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026060416142680500_dgag114-B90","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11102-024-01415-x","article-title":"Glucose metabolism outcomes after pituitary surgery in patients with acromegaly","volume":"27","author":"Pascual-Corrales","year":"2024","journal-title":"Pituitary"},{"issue":"5","key":"2026060416142680500_dgag114-B91","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416142680500_dgag114-B92","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","article-title":"Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy","volume":"164","author":"Mazziotti","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416142680500_dgag114-B93","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","article-title":"Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly","volume":"53","author":"Schmid","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"2026060416142680500_dgag114-B94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11154-024-09928-3","article-title":"Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis","volume":"26","author":"Biagetti","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"2026060416142680500_dgag114-B95","doi-asserted-by":"crossref","first-page":"e1571","DOI":"10.1210\/clinem\/dgad378","article-title":"Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416142680500_dgag114-B96","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary"},{"issue":"12","key":"2026060416142680500_dgag114-B97","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"key":"2026060416142680500_dgag114-B98","doi-asserted-by":"crossref","first-page":"1250822","DOI":"10.3389\/fendo.2024.1250822","article-title":"Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study","volume":"15","author":"Feldt-Rasmussen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026060416142680500_dgag114-B99","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","article-title":"Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus pegvisomant","volume":"73","author":"Chiloiro","year":"2021","journal-title":"Endocrine"},{"issue":"7","key":"2026060416142680500_dgag114-B100","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2018-02281","article-title":"Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies","volume":"104","author":"Feola","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416142680500_dgag114-B101","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11102-023-01370-z","article-title":"The prevalence and associated risk factors of detectable renal morphological abnormalities in acromegaly","volume":"27","author":"Bostan","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2026060416142680500_dgag114-B102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11102-025-01520-5","article-title":"Kidney function in acromegaly: evidence from a long-term observational study","volume":"28","author":"Castagna","year":"2025","journal-title":"Pituitary"},{"issue":"2","key":"2026060416142680500_dgag114-B103","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/er.2013-1071","article-title":"Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications","volume":"35","author":"Kamenick\u00fd","year":"2014","journal-title":"Endocr Rev"},{"issue":"4","key":"2026060416142680500_dgag114-B104","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.kint.2023.06.037","article-title":"A cohort study found a high risk of end-stage kidney disease associated with acromegaly","volume":"104","author":"Hong","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"2026060416142680500_dgag114-B105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tem.2018.11.007","article-title":"Sodium glucose co-transporter inhibitors in patients with acromegaly and diabetes","volume":"30","author":"Adnan","year":"2019","journal-title":"Trends Endocrinol Metabol"},{"issue":"4","key":"2026060416142680500_dgag114-B106","doi-asserted-by":"crossref","first-page":"e1075","DOI":"10.1210\/clinem\/dgaa014","article-title":"High-performance liquid chromatography-mass spectrometry-based lipid metabolite profiling of acromegaly","volume":"105","author":"Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416142680500_dgag114-B107","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocr Rev"},{"issue":"01","key":"2026060416142680500_dgag114-B108","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/a-1717-9332","article-title":"Effects of long-acting somatostatin analogues on lipid metabolism in patients with newly diagnosed acromegaly: a retrospective study of 120 cases","volume":"54","author":"Shao","year":"2022","journal-title":"Horm Metab Res"},{"issue":"25","key":"2026060416142680500_dgag114-B109","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"2026060416142680500_dgag114-B110","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.3390\/jcm14144822","article-title":"Non-invasive assessment of metabolic dysfunction-associated steatotic liver disease and cardiovascular risk in acromegaly indicates persistence of cardiac risks despite biochemical disease control","volume":"14","author":"Karadeniz","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"2026060416142680500_dgag114-B111","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1210\/clinem\/dgad490","article-title":"Nonalcoholic fatty liver disease, liver fibrosis, and utility of noninvasive scores in patients with acromegaly","volume":"109","author":"Ero\u011flu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026060416142680500_dgag114-B112","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/BF03349263","article-title":"Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults","volume":"31","author":"Giustina","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026060416142680500_dgag114-B113","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tem.2014.10.005","article-title":"Growth hormone deficiency in treated acromegaly","volume":"26","author":"Mazziotti","year":"2015","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2026060416142680500_dgag114-B114","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/EJE-12-0252","article-title":"Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy","volume":"167","author":"Nishizawa","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026060416142680500_dgag114-B115","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/jc.2015-1917","article-title":"Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment","volume":"100","author":"Reyes-Vidal","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060416142680500_dgag114-B116","doi-asserted-by":"crossref","first-page":"933039","DOI":"10.3389\/fendo.2022.933039","article-title":"The acromegaly lipodystrophy","volume":"13","author":"Freda","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2026060416142680500_dgag114-B117","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1210\/jc.2009-0026","article-title":"Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon x-ray absorptiometry","volume":"94","author":"Freda","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416142680500_dgag114-B118","doi-asserted-by":"crossref","first-page":"bvae032","DOI":"10.1210\/jendso\/bvae032","article-title":"Skeletal muscle evaluation in patients with acromegaly","volume":"8","author":"Milioto","year":"2024","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026060416142680500_dgag114-B119","doi-asserted-by":"crossref","first-page":"bvab004","DOI":"10.1210\/jendso\/bvab004","article-title":"Body composition changes with long-term pegvisomant therapy of acromegaly","volume":"5","author":"Kuker","year":"2021","journal-title":"J Endocr Soc"},{"issue":"9","key":"2026060416142680500_dgag114-B120","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"2026060416142680500_dgag114-B121","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors, and the skeleton","volume":"29","author":"Giustina","year":"2008","journal-title":"Endocr Rev"},{"issue":"4","key":"2026060416142680500_dgag114-B122","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocr Rev"},{"issue":"2","key":"2026060416142680500_dgag114-B123","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00774-024-01561-z","article-title":"Influence of disease activity and gonadal status on bone mineral density and turnover in acromegaly","volume":"43","author":"Silva","year":"2025","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"2026060416142680500_dgag114-B124","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.tem.2023.01.006","article-title":"New tools for bone health assessment in secreting pituitary adenomas","volume":"34","author":"Uygur","year":"2023","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"2026060416142680500_dgag114-B125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tem.2020.01.011","article-title":"Acromegaly and vertebral fractures: facts and questions","volume":"31","author":"Giustina","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"2026060416142680500_dgag114-B126","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1359\/JBMR.050603","article-title":"Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women","volume":"20","author":"Bonadonna","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026060416142680500_dgag114-B127","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1210\/jc.2008-0791","article-title":"Prevalence of vertebral fractures in men with acromegaly","volume":"93","author":"Mazziotti","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026060416142680500_dgag114-B128","first-page":"e5088","article-title":"Vertebral fractures occur despite control of acromegaly and are predicted by cortical volumetric bone mineral density","volume":"106","author":"Ku\u017ema","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416142680500_dgag114-B129","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3803\/EnM.2023.1782","article-title":"Increased risk of hip fracture in patients with acromegaly: a nationwide cohort study in Korea","volume":"38","author":"Kim","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"2026060416142680500_dgag114-B130","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s42000-025-00652-4","article-title":"Prevalence of vertebral fractures in patients with acromegaly: multicenter cross-sectional study","volume":"24","author":"Almalki","year":"2025","journal-title":"Hormones (Athens)"},{"issue":"7","key":"2026060416142680500_dgag114-B131","doi-asserted-by":"crossref","first-page":"e2843","DOI":"10.1210\/clinem\/dgac183","article-title":"High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly","volume":"107","author":"Frara","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416142680500_dgag114-B132","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11102-022-01266-4","article-title":"Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience","volume":"25","author":"Chiloiro","year":"2022","journal-title":"Pituitary"},{"issue":"2","key":"2026060416142680500_dgag114-B133","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1210\/jc.2014-2937","article-title":"Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis","volume":"100","author":"Mazziotti","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416142680500_dgag114-B134","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s11102-024-01439-3","article-title":"Vitamin D in pituitary driven osteopathies","volume":"27","author":"Chiloiro","year":"2024","journal-title":"Pituitary"},{"issue":"4","key":"2026060416142680500_dgag114-B135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1530\/EJE-20-0415","article-title":"Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study","volume":"183","author":"Pelsma","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416142680500_dgag114-B136","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12020-011-9486-x","article-title":"Influence of diabetes mellitus on vertebral fractures in men with acromegaly","volume":"40","author":"Mazziotti","year":"2011","journal-title":"Endocrine"},{"issue":"5","key":"2026060416142680500_dgag114-B137","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1530\/EJE-17-0154","article-title":"Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects","volume":"177","author":"Mazziotti","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416142680500_dgag114-B138","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000375450","article-title":"Bone and joint disorders in acromegaly","volume":"103","author":"Claessen","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"8","key":"2026060416142680500_dgag114-B139","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1210\/jc.2013-1460","article-title":"Vertebral fractures in patients with acromegaly: a 3-year prospective study","volume":"98","author":"Mazziotti","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026060416142680500_dgag114-B140","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s40618-025-02619-z","article-title":"Evaluation of bone density and microstructure by DXA, TBS and HR-pQCT: an assessment of cortical porosity and its association with vertebral fractures in patients with acromegaly","volume":"48","author":"Ornellas","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026060416142680500_dgag114-B141","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11102-024-01447-3","article-title":"Skeletal fragility in pituitary disease: how can we predict fracture risk?","volume":"27","author":"Bioletto","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2026060416142680500_dgag114-B142","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","article-title":"Pituitary tumors centers of excellence","volume":"49","author":"Frara","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"2026060416142680500_dgag114-B143","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12020-016-1078-3","article-title":"High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures","volume":"54","author":"Maffezzoni","year":"2016","journal-title":"Endocrine"},{"issue":"6","key":"2026060416142680500_dgag114-B144","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s11102-024-01468-y","article-title":"Novel approach to bone comorbidity in resistant acromegaly","volume":"27","author":"Frara","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2026060416142680500_dgag114-B145","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","article-title":"Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly","volume":"21","author":"Chiloiro","year":"2018","journal-title":"Pituitary"},{"issue":"3","key":"2026060416142680500_dgag114-B146","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1210\/clinem\/dgz054","article-title":"Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs","volume":"105","author":"Chiloiro","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416142680500_dgag114-B147","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/endrev\/bnae009","article-title":"Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows","volume":"45","author":"Giustina","year":"2024","journal-title":"Endocr Rev"},{"key":"2026060416142680500_dgag114-B148","first-page":"89","article-title":"Patients with active acromegaly are at high risk of 25(OH)D deficiency","volume":"6","author":"Halupczok-\u017by\u0142a","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026060416142680500_dgag114-B149","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12020-016-0890-0","article-title":"Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy?","volume":"52","author":"Mazziotti","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"2026060416142680500_dgag114-B150","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1210\/clinem\/dgad493","article-title":"Cholecalciferol use is associated with a decreased risk of incident morphometric vertebral fractures in acromegaly","volume":"109","author":"Chiloiro","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416142680500_dgag114-B151","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/cen.70010","article-title":"Static and dynamic balance is impaired in patients with long-term, well-controlled acromegaly: a cross-sectional study","volume":"103","author":"Rosendal","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2026060416142680500_dgag114-B152","first-page":"829","article-title":"Acromegaly. Reply","volume":"394","author":"Giustina","year":"2026","journal-title":"N Engl J Med"},{"issue":"15","key":"2026060416142680500_dgag114-B153","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.3390\/jcm14155511","article-title":"Collaboration between endocrinologists and dentists in the care of patients with acromegaly a narrative review","volume":"14","author":"Wi\u015bniewska","year":"2025","journal-title":"J Clin Med"},{"issue":"3","key":"2026060416142680500_dgag114-B154","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ejendo\/lvaf047","article-title":"Musculoskeletal disease in acromegaly-a population-based registry study","volume":"192","author":"Rosendal","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2026060416142680500_dgag114-B155","first-page":"S41","article-title":"Acromegalic arthropathy and sleep apnea","volume":"155","author":"Barkan","year":"1997","journal-title":"J Endocrinol"},{"issue":"6","key":"2026060416142680500_dgag114-B156","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-16-1073","article-title":"Acromegalic arthropathy in various stages of the disease: an MRI study","volume":"176","author":"Claessen","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026060416142680500_dgag114-B157","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s11102-024-01465-1","article-title":"Approach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management","volume":"27","author":"Pelsma","year":"2024","journal-title":"Pituitary"},{"issue":"6","key":"2026060416142680500_dgag114-B158","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1210\/jcem.83.6.4865","article-title":"Reversibility of joint thickening in acromegalic patients: an ultrasonography study","volume":"83","author":"Colao","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416142680500_dgag114-B159","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1530\/EJE-12-0147","article-title":"Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study","volume":"167","author":"Claessen","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026060416142680500_dgag114-B160","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s11102-019-00966-8","article-title":"Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity","volume":"22","author":"Fatti","year":"2019","journal-title":"Pituitary"},{"issue":"3","key":"2026060416142680500_dgag114-B161","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12020-022-03106-8","article-title":"Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life","volume":"77","author":"Cangiano","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"2026060416142680500_dgag114-B162","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12020-025-04331-7","article-title":"Benefits of a 12 weeks-individually tailored physical activity program in patients with Cushing's disease in remission and controlled acromegaly","volume":"90","author":"Martel-Duguech","year":"2025","journal-title":"Endocrine"},{"issue":"1","key":"2026060416142680500_dgag114-B163","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12020-018-1764-4","article-title":"Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study","volume":"63","author":"Caron","year":"2019","journal-title":"Endocrine"},{"issue":"1","key":"2026060416142680500_dgag114-B164","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40618-016-0522-9","article-title":"Peripheral nervous system assessment in acromegaly patients under somatostatin analogue therapy","volume":"40","author":"Alibas","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2026060416142680500_dgag114-B165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s11102-015-0642-9","article-title":"Median nerve conduction studies and wrist magnetic resonance imaging in acromegalic patients with carpal tunnel syndrome","volume":"18","author":"Sasagawa","year":"2015","journal-title":"Pituitary"},{"key":"2026060416142680500_dgag114-B166","doi-asserted-by":"crossref","first-page":"m1701","DOI":"10.1136\/bmj.m1701","article-title":"Carpal tunnel syndrome in acromegaly is also related to median nerve oedema","volume":"369","author":"Chanson","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"2026060416142680500_dgag114-B167","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-20-0530","article-title":"Carpal tunnel syndrome in acromegaly: a nationwide study","volume":"184","author":"Vouzouneraki","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060416142680500_dgag114-B168","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1210\/endrev\/bnae030","article-title":"Growth hormone action as a target in cancer: significance, mechanisms, and possible therapies","volume":"46","author":"Basu","year":"2025","journal-title":"Endocr Rev"},{"issue":"4","key":"2026060416142680500_dgag114-B169","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1530\/EJE-16-0178","article-title":"Management of endocrine disease: acromegaly and cancer: an old debate revisited","volume":"175","author":"Boguszewski","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060416142680500_dgag114-B170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11102-025-01513-4","article-title":"Prevalence and risk factors of colon polyps and other colonic lesions in acromegaly: from colonoscopy screening","volume":"28","author":"Hep\u015fen","year":"2025","journal-title":"Pituitary"},{"issue":"6","key":"2026060416142680500_dgag114-B171","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1210\/jc.2017-02457","article-title":"Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature","volume":"103","author":"Dal","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060416142680500_dgag114-B172","doi-asserted-by":"crossref","first-page":"e0285335","DOI":"10.1371\/journal.pone.0285335","article-title":"Risk of cancer in acromegaly patients: updated meta-analysis and systematic review","volume":"18","author":"Xiao","year":"2023","journal-title":"PLoS One"},{"issue":"10","key":"2026060416142680500_dgag114-B173","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1210\/jc.2015-2372","article-title":"The incidence of cancer among acromegaly patients: results from the acromegaly registry","volume":"100","author":"Petroff","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416142680500_dgag114-B174","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/ejendo\/lvaf029","article-title":"Acromegaly and the risk of cancer: a nationwide population-based cohort study in Korea","volume":"192","author":"Kim","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026060416142680500_dgag114-B175","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1210\/clinem\/dgae469","article-title":"Prospective, longitudinal study of cancer predictors and rates in a New York city cohort of 598 patients with acromegaly","volume":"110","author":"Freda","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416142680500_dgag114-B176","doi-asserted-by":"crossref","first-page":"e240087","DOI":"10.1530\/ERC-24-0087","article-title":"Increased cancer risk in a cohort of patients with acromegaly in Israel","volume":"32","author":"Duskin-Bitan","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"2026060416142680500_dgag114-B177","first-page":"3487","article-title":"Incidence of benign and malignant tumors in patients with acromegaly is increased: a nationwide population-based study","volume":"106","author":"Esposito","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416142680500_dgag114-B178","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s12020-024-04099-2","article-title":"Assessment of the frequency and risk factors for colorectal cancer in acromegaly","volume":"87","author":"Maia","year":"2025","journal-title":"Endocrine"},{"issue":"4","key":"2026060416142680500_dgag114-B179","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11154-025-09957-6","article-title":"Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries","volume":"26","author":"Demarchis","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"2026060416142680500_dgag114-B180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11102-025-01528-x","article-title":"Colonoscopy in acromegaly: when and why","volume":"28","author":"Dal","year":"2025","journal-title":"Pituitary"},{"issue":"6","key":"2026060416142680500_dgag114-B181","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060416142680500_dgag114-B182","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11102-012-0447-z","article-title":"Diagnostic delay is associated with psychosocial impairment in acromegaly","volume":"16","author":"Siegel","year":"2013","journal-title":"Pituitary"},{"issue":"2","key":"2026060416142680500_dgag114-B183","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11102-025-01509-0","article-title":"Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literature","volume":"28","author":"Matthesen","year":"2025","journal-title":"Pituitary"},{"issue":"4","key":"2026060416142680500_dgag114-B184","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ecl.2022.04.004","article-title":"Evaluating the impact of acromegaly on quality of life","volume":"51","author":"Coopmans","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2026060416142680500_dgag114-B185","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EJE-17-0041","article-title":"Management of endocrine disease: quality of life tools for the management of pituitary disease","volume":"177","author":"Webb","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416142680500_dgag114-B186","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11102-016-0761-y","article-title":"Update on quality of life in patients with acromegaly","volume":"20","author":"Crespo","year":"2017","journal-title":"Pituitary"},{"key":"2026060416142680500_dgag114-B187","doi-asserted-by":"crossref","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2026060416142680500_dgag114-B188","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416142680500_dgag114-B189","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2026060416142680500_dgag114-B190","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1210\/clinem\/dgad365","article-title":"MPOWERED open-label extension: long-term efficacy and safety data for oral octreotide capsules in acromegaly","volume":"108","author":"Fleseriu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416142680500_dgag114-B191","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/clinem\/dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","volume":"110","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"(4)","key":"2026060416142680500_dgag114-B192","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1210\/clinem\/dgaf579","article-title":"Rapid and sustained response of biochemically uncontrolled acromegaly to once-daily oral paltusotine treatment","volume":"111","author":"Biller","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416142680500_dgag114-B193","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/cen.15193","article-title":"Are oral somatostatin receptor ligands moving closer to becoming a reality?","volume":"102","author":"McLaren","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026060416142680500_dgag114-B194","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.2008-0669","article-title":"Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant","volume":"93","author":"Neggers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416142680500_dgag114-B195","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","article-title":"State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis","volume":"107","author":"van der Meulen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060416142680500_dgag114-B196","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fendo.2017.00040","article-title":"Predictors of quality of life in acromegaly: no consensus on biochemical parameters","volume":"8","author":"Geraedts","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026060416142680500_dgag114-B197","doi-asserted-by":"crossref","first-page":"1601661","DOI":"10.3389\/fendo.2025.1601661","article-title":"Fatigue in acromegaly patients: a scoping review","volume":"16","author":"Wang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026060416142680500_dgag114-B198","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"issue":"1","key":"2026060416142680500_dgag114-B199","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11102-015-0681-2","article-title":"SAGIT\u00ae: clinician-reported outcome instrument for managing acromegaly in clinical practice\u2013development and results from a pilot study","volume":"19","author":"Giustina","year":"2016","journal-title":"Pituitary"},{"key":"2026060416142680500_dgag114-B200","doi-asserted-by":"crossref","first-page":"1516131","DOI":"10.3389\/fendo.2025.1516131","article-title":"Patient perspectives on acromegaly disease burden: insights from a community meeting","volume":"16","author":"Shah","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2026060416142680500_dgag114-B201","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1210\/clinem\/dgad141","article-title":"Mortality in acromegaly diagnosed in older individuals in is higher in women compared to the general population","volume":"108","author":"Biagetti","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416142680500_dgag114-B202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3803\/EnM.2024.2285","article-title":"Long-term prognosis and systemic impact of acromegaly: analyses utilizing national health insurance data","volume":"40","author":"Hong","year":"2025","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"2026060416142680500_dgag114-B203","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40618-024-02519-8","article-title":"Diagnostic delay, older age, and hormonal levels at diagnosis affect disease burden and mortality in acromegaly","volume":"48","author":"Gasco","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026060416142680500_dgag114-B204","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060416142680500_dgag114-B205","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11154-024-09875-z","article-title":"The changing landscape of acromegaly \u2013 an epidemiological perspective","volume":"25","author":"Rosendal","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"2026060416142680500_dgag114-B206","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026060416142680500_dgag114-B207","doi-asserted-by":"crossref","first-page":"e250247","DOI":"10.1530\/EC-25-0247","article-title":"Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis","volume":"14","author":"Tritos","year":"2025","journal-title":"Endocr Connect"},{"issue":"6","key":"2026060416142680500_dgag114-B208","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","article-title":"Pegvisomant in acromegaly: an update","volume":"40","author":"Giustina","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026060416142680500_dgag114-B209","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"2026060416142680500_dgag114-B210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11102-019-00977-5","article-title":"Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT\u00ae validation study","volume":"22","author":"Giustina","year":"2019","journal-title":"Pituitary"},{"issue":"7","key":"2026060416142680500_dgag114-B211","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2017-00142","article-title":"High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study","volume":"102","author":"Giustina","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416142680500_dgag114-B212","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","article-title":"Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review","volume":"14","author":"Fleseriu","year":"2011","journal-title":"Pituitary"},{"issue":"1","key":"2026060416142680500_dgag114-B213","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-024-01479-9","article-title":"IGF-I levels during standard lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly","volume":"28","author":"Chiloiro","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"2026060416142680500_dgag114-B214","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF03349183","article-title":"Resistance to somatostatin analogs in acromegaly: an evolving concept?","volume":"29","author":"Gola","year":"2006","journal-title":"J Endocrinol Invest"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag114\/68130174\/dgag114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S51\/68130174\/dgag114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S51\/68130174\/dgag114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:14:53Z","timestamp":1780604093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/Supplement_1\/S51\/8660331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":214,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag114","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,22]]}}}